OBJECTIVES: This study aimed to compare the tolerability and efficacy of two different titrations of paroxetine (slow and standard) in a population of cancer patients with depression. METHODS: This randomized open trial included 30 cancer patients with depression (major depressive disorder, dysthymic disorder, or adjustment disorder with depressed mood) and aimed to compare the safety of slow up-titration (arm A) versus standard up-titration (arm B) of paroxetine chlorhydrate. In both arms, the maximum final dose was 20 mg/day. Patients were evaluated at baseline and after 2, 4, and 8 weeks with rating scales for depression and anxiety (MADRS, HADS, HAM-A, CGI), quality of life (EORTC-QLQ-30), and side effects (DOTES, SIDE). RESULTS:Thirty consecutive cancer patients (F = 21; M = 9) meeting DSM-IV TR criteria for mood disorders (MD) were enrolled in the study and randomly assigned to slow or standard paroxetine titration. Both treatment groups showed a significant mood improvement (change in MADRS total score) from baseline to end point (arm A-F(2,18) = 33.68 p < 0.001; arm B-F(2,12) = 6.97 p < 0.005). A significantly higher rate of patients in arm A compared with arm B showed no side effects after 2 weeks (40% vs. 6.7%, respectively). A multinomial logistic regression confirmed such differences between arms (chi square = 20.89 p = 0.004). The self-evaluating scale (SIDE) confirmed this difference: 60% of subjects in arm B perceived side effects compared to only 11.1% of patients in arm A. CONCLUSIONS: The results of this study suggest that slow paroxetine up-titration is better tolerated and at least as effective as the standard paroxetine up-titration in cancer patients with depression.
RCT Entities:
OBJECTIVES: This study aimed to compare the tolerability and efficacy of two different titrations of paroxetine (slow and standard) in a population of cancerpatients with depression. METHODS: This randomized open trial included 30 cancerpatients with depression (major depressive disorder, dysthymic disorder, or adjustment disorder with depressed mood) and aimed to compare the safety of slow up-titration (arm A) versus standard up-titration (arm B) of paroxetine chlorhydrate. In both arms, the maximum final dose was 20 mg/day. Patients were evaluated at baseline and after 2, 4, and 8 weeks with rating scales for depression and anxiety (MADRS, HADS, HAM-A, CGI), quality of life (EORTC-QLQ-30), and side effects (DOTES, SIDE). RESULTS: Thirty consecutive cancerpatients (F = 21; M = 9) meeting DSM-IV TR criteria for mood disorders (MD) were enrolled in the study and randomly assigned to slow or standard paroxetine titration. Both treatment groups showed a significant mood improvement (change in MADRS total score) from baseline to end point (arm A-F(2,18) = 33.68 p < 0.001; arm B-F(2,12) = 6.97 p < 0.005). A significantly higher rate of patients in arm A compared with arm B showed no side effects after 2 weeks (40% vs. 6.7%, respectively). A multinomial logistic regression confirmed such differences between arms (chi square = 20.89 p = 0.004). The self-evaluating scale (SIDE) confirmed this difference: 60% of subjects in arm B perceived side effects compared to only 11.1% of patients in arm A. CONCLUSIONS: The results of this study suggest that slow paroxetine up-titration is better tolerated and at least as effective as the standard paroxetine up-titration in cancerpatients with depression.
Authors: Gary Rodin; Nancy Lloyd; Mark Katz; Esther Green; Jean A Mackay; Rebecca K S Wong Journal: Support Care Cancer Date: 2006-10-21 Impact factor: 3.603
Authors: Dominique L Musselman; Wendy I Somerset; Ying Guo; Amita K Manatunga; Maryfrances Porter; Suzanne Penna; Barbara Lewison; Rebecca Goodkin; Kathryn Lawson; David Lawson; Dwight L Evans; Charles B Nemeroff Journal: J Clin Psychiatry Date: 2006-02 Impact factor: 4.384
Authors: D Razavi; J F Allilaire; M Smith; A Salimpour; M Verra; B Desclaux; P Saltel; I Piollet; A Gauvain-Piquard; C Trichard; B Cordier; R Fresco; E Guillibert; D Sechter; J P Orth; M Bouhassira; P Mesters; P Blin Journal: Acta Psychiatr Scand Date: 1996-09 Impact factor: 6.392
Authors: Joseph A Roscoe; Gary R Morrow; Jane T Hickok; Karen M Mustian; Jennifer J Griggs; Sara E Matteson; Peter Bushunow; Raman Qazi; Brian Smith Journal: Breast Cancer Res Treat Date: 2005-02 Impact factor: 4.872
Authors: Lindsey I Sinclair; David M Christmas; Sean D Hood; John P Potokar; Andrea Robertson; Andrew Isaac; Shrikant Srivastava; David J Nutt; Simon J C Davies Journal: Br J Psychiatry Date: 2009-06 Impact factor: 9.319
Authors: Erik E Rabin; Miri Kim; Andreas Mozny; Krislyn Cardoza; April C Bell; Lijie Zhai; Prashant Bommi; Kristen L Lauing; Amanda L King; Terri S Armstrong; Theresa L Walunas; Deyu Fang; Ishan Roy; John D Peipert; Erica Sieg; Xinlei Mi; Christina Amidei; Rimas V Lukas; Derek A Wainwright Journal: Brain Behav Immun Health Date: 2022-03-23